IDH2 and glioblastoma: The higher proportion of TERT promotor mutations (68.3%) and EGFRvIII expression (47.9%) in those IDH-wt astrocytoma that where tested, strongly suggests that a substantial number of these cases would be reclassified as “molecular IDH-wt glioblastoma CNS WHO grade 4” according to WHO 2021 criteria.